设计排除:入组标准限制老年人参与SARS-CoV-2疫苗临床试验
常见排除标准如高血压、糖尿病和癌症在老年人中更普遍,且应用时与较低平均参与者年龄相关。
要点
- ≥65岁人群仅占疫苗试验参与者的9%,远低于其占美国人口18%和COVID-19死亡76%的比例。
- 仅35%的研究设明确年龄上限,但高血压、糖尿病、癌症等排除标准 disproportionately 限制老年人。
- 应用这些常见慢性病排除标准的研究平均参与者年龄更低,提示排除标准加剧老年代表性不足。
核心结论
- SARS-CoV-2疫苗临床试验中老年人代表性持续不足,常见排除标准 disproportionately 限制其参与。
- 需重新考虑 disproportionately 影响高风险老年人群的排除标准,以增强试验结果的普遍性和适用性。
研究设计与样本
- 提取试验特征、参与者年龄数据和入组标准,用报告汇总统计建模年龄分布以估计老年人代表性。
- 系统评估对老年人影响更大的疾病作为排除标准的使用情况,并比较其在美国人群中的年龄别患病率。
- 检查排除常见慢性病的试验是否平均入组更年轻的参与者人群。
主要发现
- 估计全部试验707,378名参与者中63,223名(9%)年龄≥65岁。
- 老年人占美国人口18%、占COVID-19相关死亡的76%。
- 仅35%的研究有明确年龄上限标准。
- 高血压、糖尿病和癌症等常见排除标准在老年人中更普遍,应用时与较低平均参与者年龄相关。
关键数值与推荐
- 老年人(≥65岁)占试验参与者9%(63,223/707,378),占美国人口18%,占COVID-19死亡76%。
- 35%的研究设明确年龄上限。
- 常见排除标准包括高血压、糖尿病和癌症,这些疾病在老年人中患病率更高。
临床怎么用
- 解读SARS-CoV-2疫苗试验结果时需注意老年人代表性不足可能限制外推性。
- 设计疫苗临床试验时应审慎评估排除标准,避免 disproportionately 排除患有常见慢性病的老年人。
- 监管与伦理审查可关注入组标准对老年高危人群公平代表性的影响。
局限性
- 年龄分布基于报告汇总统计建模估计,非个体参与者数据。
- 仅纳入ClinicalTrials.gov注册试验,未涵盖其他注册平台。
- 比较参照为美国人口与COVID-19死亡数据,全球外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Older adults (≥65 years) face a disproportionate burden of COVID-19 mortality yet remain underrepresented in clinical trials despite this group accounting for 76% of COVID-19 deaths. Hundreds of SARS-CoV-2 vaccine clinical trials have been registered on ClinicalTrials.gov; however, the extent of older adult representation remains unclear. Our objective was to evaluate the representation of older adults in SARS-CoV-2 vaccine clinical trials registered on ClinicalTrials.gov and identify enrollment criteria that disproportionately limit older adult participation. METHODS: We conducted a retrospective, cross-sectional analysis of 207 global SARS-CoV-2 vaccine clinical trials registered on ClinicalTrials.gov between November 1, 2019, and September 30, 2025. For each trial, we extracted trial characteristics, participant age data, and enrollment criteria. Age distributions were modeled using reported summary statistics to estimate older adult representation. We compared these estimates to the US population age distribution and COVID-19 mortality. To identify contributing factors to underrepresentation, we systematically evaluated trial eligibility criteria for conditions that disproportionately affect older populations. We compared the age-specific prevalence of these conditions in the US population to their use as exclusion criteria across trials. Additionally, we examined whether trials that excluded common chronic conditions enrolled younger participant populations on average. RESULTS: We estimate that 63,223 out of 707,378 (9%) of participants across all trials were aged ≥65, despite older adults accounting for 18% of the US population and 76% of COVID-19-related deaths. Although only 35% of studies had explicit criteria for an upper age limit, we identified common study exclusion criteria, such as hypertension, diabetes, and cancer that are more prevalent among older adults and associated with lower mean participant ages when applied. CONCLUSION: These findings highlight persistent barriers to equitable inclusion of older adults in vaccine research and underscore the need to reconsider exclusion criteria that disproportionately affect this high-risk population to enhance the generalizability and applicability of clinical trial outcomes.
引用
- Johnson TN, Chu HY, Fohner AE, et al. Exclusion by design: enrollment criteria limit older adult participation in SARS-CoV-2 vaccine clinical trials. J Clin Epidemiol. 2026. PMID: 42184871. doi:10.1016/j.jclinepi.2026.112343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。